BridgeBio Oncology Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for BridgeBio Oncology Therapeutics, Inc. (BBOT) - Annual data in millions USD
BreakdownFY 2024FY 2023
Period EndingDec 2024Dec 2023
Operating Activities
Net Income-74.28-64.70
Depreciation & Amortization0.210.09
Stock Based Compensation4.4316.47
Change in Working Capital15.59-3.94
Change in Accounts Payable2.500.27
Change in Other Working Capital13.10-4.20
Other Operating Activities0.560.00
Net Cash from Operating Activities-55.03-52.08
Investing Activities
Capital Expenditures-0.05-0.41
Purchases of Investments-122.890.00
Other Investing Activities2.41-2.41
Net Cash from Investing Activities-120.53-2.82
Financing Activities
Debt Repayment-0.210.00
Common Stock Issued1.113.62
Other Financing Activities-0.580.00
Net Cash from Financing Activities206.2955.12
Summary
Net Change in Cash30.730.23
Cash at Beginning of Period0.000.03
Cash at End of Period1.700.25
Free Cash Flow-55.08-52.49